AN2 Therapeutics, Inc. Common Stock (ANTX) Stock
Key stats
- Market cap
- $169.23M
- Price / Earnings ratio
- -4.7x
- EPS (TTM)
- -$0.92
- Volume
- Loading
- 52-week high
- $7.19
- 52-week low
- $1.00
Source: third-party data provider, as of November 13, 2026
Compare with ANTX
Recent news

AN2 Therapeutics Reports Q3 2026 Net Loss of $8.0 Million
AN2 Therapeutics Reports Q3 2026 Net Loss of $8.0 Million
ANTX

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
ANTX

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
ANTX

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
ANTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.20
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.16
- MACD histogram
- 0.08
- SMA 50
- $4.67
- Price below SMA 50
- EMA 50
- $4.50
- Price below EMA 50
- SMA 200
- $4.19
- Price above SMA 200
- EMA 200
- $3.81
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

AN2 Therapeutics Reports Q3 2026 Net Loss of $8.0 Million
AN2 Therapeutics Reports Q3 2026 Net Loss of $8.0 Million
ANTX

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
ANTX

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
ANTX

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
ANTX

AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics to Participate at Upcoming Investor Conferences
ANTX

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
ANTX

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
ANTX

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
ANTX

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
ANTX

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
ANTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About AN2 Therapeutics, Inc. Common Stock
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric E. Easom | Co-Founder, CEO, President & Chairman of the Board | 1968 |
| Ms. Lucy O. Day CPA | CFO, & Principal Financial Officer | 1960 |
| Mr. Joshua M. Eizen J.D. | Chief Legal Officer, COO & Corporate Secretary | 1979 |
| Mr. Joseph S. Zakrzewski | Co-Founder & Independent Director | 1962 |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor | 1948 |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder, Senior VP of Research Fellow & Head of Biology | — |
| Ms. Sarah Williams | Vice President of Controller & Principal Accounting Officer | 1988 |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer | 1966 |
| Mr. Vince Hernandez | Senior VP of Research & Head of Chemistry | — |
| Dr. Cameron Trenor III | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.20
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.16
- MACD histogram
- 0.08
- SMA 50
- $4.67
- Price below SMA 50
- EMA 50
- $4.50
- Price below EMA 50
- SMA 200
- $4.19
- Price above SMA 200
- EMA 200
- $3.81
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +155.2 | +31.9 | -7.5 | +15.0 | +13.8 | -0.5 | -2.9 | -19.4 | +2.5 |



